TScan Therapeutics’ (TCRX) Outperform Rating Reaffirmed at Wedbush

TScan Therapeutics (NASDAQ:TCRX)‘s stock had its “outperform” rating reiterated by equities research analysts at Wedbush in a research note issued to investors on Tuesday, Benzinga reports. They presently have a $10.00 price objective on the stock. Wedbush’s price objective would suggest a potential upside of 39.08% from the stock’s previous close.

Separately, HC Wainwright reiterated a “buy” rating and set a $15.00 target price on shares of TScan Therapeutics in a research note on Thursday, March 7th.

TScan Therapeutics Stock Performance

Shares of TScan Therapeutics stock traded up $0.07 on Tuesday, reaching $7.19. The stock had a trading volume of 131,679 shares, compared to its average volume of 186,369. The business’s 50-day moving average price is $7.08 and its two-hundred day moving average price is $5.74. The company has a debt-to-equity ratio of 0.18, a quick ratio of 6.51 and a current ratio of 6.51. TScan Therapeutics has a fifty-two week low of $1.62 and a fifty-two week high of $9.00. The stock has a market cap of $344.26 million, a P/E ratio of -3.90 and a beta of 0.90.

TScan Therapeutics (NASDAQ:TCRX) last issued its quarterly earnings data on Wednesday, March 6th. The company reported ($0.21) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.08. TScan Therapeutics had a negative net margin of 423.86% and a negative return on equity of 60.65%. The business had revenue of $7.21 million during the quarter, compared to analysts’ expectations of $2.94 million. On average, sell-side analysts forecast that TScan Therapeutics will post -1.03 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently added to or reduced their stakes in TCRX. Letko Brosseau & Associates Inc. acquired a new position in TScan Therapeutics during the 3rd quarter worth about $83,000. Pale Fire Capital SE acquired a new position in TScan Therapeutics during the 3rd quarter worth about $42,000. abrdn plc acquired a new position in TScan Therapeutics during the 4th quarter worth about $1,166,000. Finally, Cannon Global Investment Management LLC acquired a new position in TScan Therapeutics during the 1st quarter worth about $139,000. Institutional investors and hedge funds own 82.83% of the company’s stock.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.